New Healthcare market report from Business Monitor International: "Portugal Pharmaceuticals & Healthcare Report Q1 2013"

Boston, MA -- (SBWire) -- 03/19/2013 --BMI View: Portugal's pharmaceutical and healthcare sector has been transformed since the intervention of the EU, IMF and ECB as part of the country's EUR78bn economic rescue package approved in May 2011. The latest review states that Portugal has already made considerable savings in the healthcare sectors, with changes such as the introduction of e-prescriptions and prescribing by active ingredients, changes to reference pricing, reductions in pharmacy margins and price cuts just some of the measures in place. The impact on the market has been widespread. Spending has been slashed and both domestic and multinational pharmaceutical firms have seen their profits shrink. Data recently published by Infarmed show that Portugal has dropped from hosting 138 clinical trials in 2008 to just 87 in 2011, suggesting the country is losing its appeal as a location for research and development (R&D). Drug shortages in pharmacies are also commonplace, with a study published by Apifarma in October 2012 suggesting that parallel exports are partly to blame.

View Full Report Details and Table of Contents

Headline Expenditure Projections

- Pharmaceuticals: EUR4.47bn (US$6.21bn) in 2011 to EUR4.24bn (US$5.39bn) in 2012; -5.1% in local currency and -13.3% in US dollar terms. Forecast raised slightly from Q412 because of new historical data.
- Healthcare: EUR19.59bn (US$27.22bn) in 2011 to EUR20.16bn (US$25.60bn) in 2012; +2.9% in local currency and -6.0% in US dollar terms. Forecast raised from Q412 because of new historical data.
- Medical Devices: EUR740mn (US$1.03bn) in 2011 to EUR763mn (US$0.97bn) in 2012; +3.1% in local currency and -5.8% in US dollar terms. Forecast unchanged from Q412.

Risk/Rewards Rating: Portugal's score of 58.6 in Q113 places it at the bottom of the Pharmaceutical Risk/Reward Ratings (RRRs) table for Western Europe. The impact of cost cutting and austerity measures as part of the EU/IMF/ECB's three-year economic adjustment package, which was approved in May 2011, is taking its toll on the pharmaceutical and healthcare sector and, while Portugal is on target to meet its healthcare sector goals, we are not forecasting a return to growth in terms of pharmaceutical sales until the end of our 10-year forecast period.

Key Trends & Developments

- Apifarma published a study in October 2012 that claims that parallel exports are one of the main causes behind drug shortages in pharmacies; it believes that wholesalers prefer to export drugs as this generates greater revenues.
- One of the few growth areas in Portugal's pharmaceuticals market is the sale of OTC drugs in mass market outlets. Data from Infarmed for H112 show that sales increased by 6.1% y-o-y compared to H111, climbing to EUR15.3mn.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Nigeria Pharmaceuticals & Healthcare Report Q1 2013
- Sweden Pharmaceuticals & Healthcare Report Q1 2013
- Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2011
- Slovenia Pharmaceuticals & Healthcare Report Q1 2013
- Estonia Pharmaceuticals & Healthcare Report Q1 2013
- Kenya Pharmaceuticals & Healthcare Report Q1 2013
- Netherlands Pharmaceuticals & Healthcare Report Q1 2013
- South Korea Pharmaceuticals & Healthcare Report Q1 2013
- Mexico Pharmaceuticals & Healthcare Report Q1 2013
- Chile Pharmaceuticals & Healthcare Report Q1 2013